BioLineRx grants Ikaria rights to BL1040
Executive Summary
About a month after receiving positive preliminary results of a Phase I/II trial for BL1040, BioLineRx has granted Ikaria (acute care products) exclusive worldwide rights. It is a liquid polymer for preventing ventricular remodeling after a patient suffers from acute myocardial infarction.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice